Treatment for multiple myeloma is focused on therapies that decrease the clonal plasma cell population and consequently decrease the signs and symptoms of disease. If the disease is completely asymptomatic (i.e. there is a paraprotein and an abnormal bone marrow population but no end-organ damage), as in<unk> , treatment is typically deferred, or restricted to clinical trials. They are generally responsive to IL-1β neutralisation.
Smouldering myeloma
Multiple myeloma
Monoclonal gammopathy of undetermined significance
AL amyloidosis
POEMS syndrome
Plasma cell leukemia
Monoclonal gammopathy of renal significance
Secondary systemic amyloidosis